Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies

被引：0
|
作者：
Stefanie Förderreuther
Qi Zhang
Virginia L. Stauffer
Sheena K. Aurora
Miguel J. A. Láinez
机构：
[1] Ludwig Maximilian University,Department of Neurology
[2] Sanofi,undefined
[3] Eli Lilly and Company,undefined
[4] Lilly Corporate Center,undefined
[5] Hospital Clínico Universitario,undefined
[6] Universidad Católica de Valencia,undefined
来源：
The Journal of Headache and Pain | 2018年 / 19卷
关键词：
Galcanezumab; Migraine; Preventive; Persistence; Maintenance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Evaluation of cardiovascular risks in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled studies
    Oakes, T. M.
    Kovacs, R.
    Rosen, N.
    Doty, E. G.
    Kemmer, P.
    Aurora, S. K.
    Camporeale, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 295 - 295
  • [32] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Bo Hu
    Gang Li
    Xiaohong Li
    Shan Wu
    Tingmin Yu
    Xiang Li
    Hongru Zhao
    Zhihua Jia
    Junpeng Zhuang
    Shengyuan Yu
    The Journal of Headache and Pain, 2022, 23
  • [33] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Hu, Bo
    Li, Gang
    Li, Xiaohong
    Wu, Shan
    Yu, Tingmin
    Li, Xiang
    Zhao, Hongru
    Jia, Zhihua
    Zhuang, Junpeng
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [34] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) (vol 20, 75, 2019)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [35] Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert
    NEUROLOGY, 2020, 94 (15)
  • [36] Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
    Skljarevski, Vladimir
    Matharu, Manjit
    Millen, Brian A.
    Ossipov, Michael H.
    Kim, Byung-Kun
    Yang, Jyun Yan
    CEPHALALGIA, 2018, 38 (08) : 1442 - 1454
  • [37] 100% RESPONSE RATE TO GALCANEZUMAB IN PATIENTS WITH EPISODIC MIGRAINE: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
    Nagy, A. J.
    Pearlman, E.
    Ruff, D.
    Day, K.
    Aurora, S. K.
    Rosen, N.
    CEPHALALGIA, 2018, 38 : 63 - 64
  • [38] 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies
    Nagy, Abraham Jim
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Rosen, Noah
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [39] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, H. C.
    Wang, S.
    Skljarevski, V
    Ahl, J.
    Millen, B.
    Aurora, S. K.
    Yang, J.
    HEADACHE, 2017, 57 (08): : 1336 - 1337
  • [40] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    CEPHALALGIA, 2017, 37 : 338 - 338
12345